Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 3/20 | 0.35 |
| ▸ | RARA | P10276 | 2/20 | 0.35 |
| ▸ | RARG | P13631 | 1/20 | 0.35 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.35 |
| ▸ | CYP21A2 | P08686 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 5/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
| ▸ | RXRA | P19793 | 2/20 | 0.32 |
| ▸ | RXRB | P28702 | 2/20 | 0.32 |
| ▸ | RXRG | P48443 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15744325 | 0.92 | RARB (0.35) | RARBRARARARGMAOBNPC1 | |
| SCHEMBL13002204 | 0.91 | RARB (0.36) | RARBRARARARGCYP11B1MAOB | |
| SCHEMBL503178 | 0.90 | RARB (0.35) | RARBRARARARGMAOBNPC1 | |
| SCHEMBL17108380 | 0.90 | RARB (0.35) | RARBRARARARGMAOBNPC1 | |
| SCHEMBL15786639 | 0.90 | MAOB (0.40) | RARBRARARARGMAOBTAAR1 | |
| SCHEMBL15744500 | 0.88 | RARB (0.34) | RARBRARARARGMAOBNPC1 | |
| SCHEMBL16841956 | 0.88 | RARB (0.34) | RARBRARARARGMAOBNPC1 | |
| SCHEMBL15744313 | 0.88 | RARB (0.34) | RARBRARARARGMAOBNPC1 | |
| SCHEMBL15744312 | 0.88 | RARB (0.34) | RARBRARARARGMAOBNPC1 | |
| SCHEMBL19393985 | 0.87 | RARB (0.34) | RARBRARARARGMAOBNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9546181-B2 | Compound having perfluoroalkyl terminal group and CF2O bonding group, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2017-01-17 | — | — | US | disclosed |
| US-9365774-B2 | Liquid crystal compound having CF2OCF3 at terminal, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2016-06-14 | — | — | US | disclosed |
| US-9365774-B2 | Liquid crystal compound having CF2OCF3 at terminal, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2016-06-14 | — | — | US | disclosed |
| US-20160152636-A1 | COMPOUND HAVING PERFLUOROALKYL TERMINAL GROUP AND CF2O BONDING GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2016-06-02 | — | — | US | disclosed |
| EP-2735599-B1 | Liquid crystal compound having CF2OCF3 at terminal, liquid crystal composition and liquid crystal display device | JNC CORP (JP) | 2015-04-29 | — | — | EP | disclosed |
| US-20140145113-A1 | LIQUID CRYSTAL COMPOUND HAVING CF2OCF3 AT TERMINAL, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2014-05-29 | — | — | US | disclosed |
| US-20140145113-A1 | LIQUID CRYSTAL COMPOUND HAVING CF2OCF3 AT TERMINAL, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2014-05-29 | — | — | US | disclosed |
| EP-2735599-A1 | Liquid crystal compound having CF2OCF3 at terminal, liquid crystal composition and liquid crystal display device | JNC Corporation (JP) | 2014-05-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152636-A1 | COMPOUND HAVING PERFLUOROALKYL TERMINAL GROUP AND CF2O BONDING GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | PFN1, AFF1, RCC1 | RARB 2000/4885RARA 1035/4885RARG 2254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.